elranatamab
pfizer
['cart,(-cartitude)', 'elranatamab']
elranatamab sc shows a response rate 54%, crs ~67% (grade 1/2), median pfs not reached at a median follow-up of 8.1 months #cartsm #asco22 #asco22_szu #mediq22asco #eha2022
Chief of Myeloma @MSKCancerCenter | Chair @ALLIANCE_org #mmsm Comm. |Physician ? Provider| @ASH_hematology @ASTCT @ASCO |married to @ZainabShd | #BMTsm #CARTsm